Oncology News | pharmaphorum

News

Europe approves Roche's Tecentriq liver cancer combination

The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients with the most common form of liver cancer.

News

Jounce shares crash after it abandons immunotherapy combinat...

Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy will likely fail to produce results in non-small cell l

News

Sanofi to acquire Kiadis and NK cell tech for $353 million

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million).

News

FDA sets Feb decision date for Libtayo lung cancer challenge...

The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche

News

NICE changes stance on Keytruda for first-line head and neck...

As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and n

News

David Hung’s Nuvation Bio seals merger with blank cheque fir...

Two years after quietly forming cancer start-up Nuvation Bio, ex-Axovant and Medivation CEO David Hung has agreed a big merger that will take it public – and provide more than $850 million

Europe approves Roche's Tecentriq liver cancer combination

Jounce shares crash after it abandons immunotherapy combinat...

Sanofi to acquire Kiadis and NK cell tech for $353 million

FDA sets Feb decision date for Libtayo lung cancer challenge...

NICE changes stance on Keytruda for first-line head and neck...

David Hung’s Nuvation Bio seals merger with blank cheque fir...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks